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Abstract
Objectives—Newborn screening for X-linked adrenoleukodystrophy utilizes tandem mass 
spectrometry to analyze dried-blood spot specimens. Quality control materials (dried-blood spots 
enriched with hexacosanoyl lysophosphatidylcholine) were prepared and stored at different 
temperatures for up to 518 days to evaluate the stability of this biomarker for X-linked 
adrenoleukodystrophy.
Design and methods—Dried-blood spot storage included desiccant (45, 171, and 518 days) or 
omitted desiccant (53 days at >90% relative humidity). Specimens were stored for 171 and 518 
days at −20 °C, 4 °C, ambient temperature, and 37 °C. Each weekday for 45 days, a bag of 
specimens stored at 4 °C was warmed to ambient temperature and one specimen was removed for 
storage at −80 °C. Specimens were analyzed by high-performance liquid-chromatography 
electrospray ionization tandem mass spectrometry and data was plotted as concentration 
(micromoles per liter) vs. time. Linear regression provided slope and y-intercept values for each 
storage condition.
Results—Small slope values (0.01 or less) and y-intercept values close to the enrichment 
indicated less than 11% loss of hexacosanoyl lysophosphatidylcholine under all storage conditions 
tested.
Conclusions—Quality control materials for X-linked adrenoleukodystrophy are stable for at 
least 1 year when stored with desiccant.
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Introduction
X-linked adrenoleukodystrophy (X-ALD1) is a peroxisomal disorder [1] caused by 
mutations in the peroxisomal transmembrane ALD protein (ALDP, ABCD1) [2]. The 
biochemical defect associated with X-ALD is an accumulation of very long-chain fatty 
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acids, which has been shown to result in the accumulation of C26:0-lysophosphatidylcholine 
(C26:0-LPC) [3]. Some newborn screening programs are either already performing newborn 
screening for X-ALD (New York) or may do so in the near future (Connecticut). Dried-
blood spots (DBS) were prepared with C26:0-LPC-enriched whole blood, and stored under 
different conditions for up to 18 months. C26:0-LPC was measured to determine its stability 




Hexacosanoyl lysophosphatidylcholine (C26:0-LPC) and 2H4-hexacosanoyl 
lysophosphatidylcholine (2H4-C26:0-LPC) were from Avanti Polar Lipids (Alabaster, AL). 
Ammonium acetate, HPLC–MS grade methanol and HPLC–MS grade acetonitrile were 
from Fisher Scientific.
Dried-blood spots
Packed red cells and serum were obtained from anonymous donors (Tennessee Blood 
Services), the red cells were washed 3 times with saline, and serum was added to achieve a 
final hematocrit of 50 ± 1% [4]. The blood was frozen and thawed to lyse the red cells, 
filtered through cheesecloth to remove small clots, enriched with C26:0-LPC, and then 
spotted onto Whatman 903 filter paper (100 μL spots). The blood spots were dried overnight 
and stored with desiccant at −20 °C.
Dried-blood spot enrichment
DBS Quality Control (QC) materials were prepared by enriching lysed blood with C26:0-
LPC to target concentrations of 0 μM (no enrichment), 1 μM, and 10 μM. The C26:0-LPC 
stock solution was 1 mg/mL in methanol. Stability study materials were enriched to a target 
concentration of 4 μM (except the high-humidity stability study samples which were 
enriched to a target concentration of 10 μM). Using HPLC–ESI-MS/MS (see the HPLC–
ESI-MS/MS analysis section), C26:0-LPC was measured in the DBS to assess homogeneity 
and characterize their enrichment. The means and standard deviations of the different 
materials were determined by analysis on 20 different days [5].
Stability studies
DBS enriched with C26:0-LPC were labeled to indicate their storage temperature and the 
number of days of exposure to that temperature. All DBS were placed in mylar zip-closure 
bags with desiccant (except the high-humidity samples), and bags were stored at −20 °C, 
4 °C, ambient room temperature, and 37 °C. The high-humidity samples were placed in an 
un-zipped mylar bag (no desiccant) in a closed container with water-saturated paper towels 
at ambient room temperature. For the 6-month and 18-month stability studies a DBS sample 
1X-ALD (X-linked adrenoleukodystrophy), ALDP (adrenoleukodystrophy protein), C26:0-LPC (hexacosanoyl 
lysophosphatidylcholine), DBS (dried-blood spot), QC (quality control), HPLC–ESI-MS/MS (high-performance liquid 
chromatography electrospray ionization tandem mass spectrometry).
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was removed from each mylar bag (temperature condition) every 2 weeks and then stored at 
−80 C. Based upon results from the 6-month study, the samples intended for a 12-month 
study were stored for 18 months. To simulate storage conditions for DBS used on a daily 
basis as QC materials [4,6], some DBS stored at 4 °C were removed every weekday and 
allowed to warm to room temperature; the mylar zip-closure bag was opened for several 
minutes and a DBS specimen was removed and stored at −80 °C. This working bag study 
was conducted for 45 days. The high-humidity study (also with DBS specimen removal 
every weekday) was conducted for 53 days.
HPLC–ESI-MS/MS analysis
At the completion of stability studies the DBS specimens were removed from −80 °C 
storage, allowed to warm to room temperature, and each specimen was analyzed in 
triplicate. The throughput of a negative ion-mode HPLC–ESI-MS/MS method to detect 
C26:0-LPC in DBS [7] was improved to achieve an HPLC analysis time of 1 min per sample 
by increasing the mobile phase flow rate to 0.45 mL/min. The isocratic mobile phase was 
50:50 methanol/acetonitrile containing 5 mM ammonium acetate. Ion source parameters 
were optimized for this higher flow rate by increasing Gas 1 (desolvation gas) to 35, Gas 2 
(heater gas) to 20, and the temperature to 400 ° C. Analyte and internal standard were 
monitored with the MRM pairs 620.6 → 395.3 and 624.6 → 399.3, respectively. The C26:0-
LPC was quantitated by the following calculation [8–10]: (C26:0-LPC peak area/2H4-C26:0-
LPC peak area) × [2H4-C26:0-LPC] × 14.29. The [2H4-C26:0-LPC] in extraction solution 
was 0.2 μM, and 14.29 = 100/7, which represents the dilution of blood from a 3/16″ punch 
[11] in 100 μL of extraction solution. For the stability studies at different temperatures 
results are shown (Table 1) as the fraction of remaining C26:0-LPC relative to C26:0-LPC in 
samples stored at −80 °C for the duration of the stability study. This fraction is the quotient 
of the y-intercept (from linear regression) and the concentration of C26:0-LPC measured in 
samples stored at −80 °C for the duration of the stability study.
Results
Quality control materials
Zero enrichment QC material was characterized as 0.03 μM C26:0-LPC (95% confidence 
interval 0.01 to 0.05 μM), 1 μM enriched QC material was characterized as 0.98 μM (95% 
confidence interval 0.85 to 1.11 μM), and 10 μM enriched QC material was characterized as 
9.21 μM (95% confidence interval 8.15 to 10.27 μM).
Stability studies
Linear regression of the C26:0-LPC quantities in DBS stored with desiccant for at least 6 
months resulted in small slopes at 4 temperatures [−20 °C (0.0003), 4 °C (−0.0005), ambient 
temperature (−0.001), and 37 °C (−0.0029)]. Linear regression of the measured C26:0-LPC 
resulted in a slope of −0.0005 for DBS stored at 4 °C for 45 days with desiccant but 
removed daily from refrigeration with opening of their storage bag simulating daily use of 
QC materials. Storage at ambient temperature with relative humidity > 90% for 53 days 
resulted in a linear regression of C26:0-LPC with a slope of −0.0115. These results are 
summarized in Table 1.
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The enriched C26:0-LPC was stable in DBS under all of the conditions tested, as evidenced 
by small slope values and fractions close to 1.00 for C26:0-LPC in samples stored at 
different temperatures compared to samples stored at −80 °C for the duration of the stability 
study. X-ALD QC materials are currently available on a pilot basis from the Newborn 
Screening Quality Assurance Program at the Centers for Disease Control and Prevention.
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